Video

Can Liraglutide Delay Diabetes Onset?

Researchers compared time to onset of diabetes in a group of patients with obesity and pre-diabetes treated with liraglutide or placebo.

In a randomized, double-blind, placebo-controlled study comparing liraglutide 3 mg daily to placebo, the authors determined time to onset of diabetes as the main outcome measure. Results were published in the Lancet.

Patients in the study were classified as having pre-diabetes with elevated BMIs and were enrolled as an adjunct to dieting and increasing physical activity.

The time to onset of diabetes was 2.7 times longer in the liraglitide group.

Two percent of patients in the liraglutide group were diagnosed with diabetes vs 6% in the placebo group. Liraglutide also induced greater weight loss than placebo.

The authors concluded that liraglutide might reduce the risk the risk of diabetes in patients with obesity and pre-diabetes.

Related Videos
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
Viet Le, DMSc, PA-C | Credit: APAC
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
Diabetes Dialogue: Latest Updates on Semaglutide Shortage, Data | Image Credit: HCPLive
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
© 2024 MJH Life Sciences

All rights reserved.